Advancing drug innovation for neglected diseases-criteria for lead progression.

The current drug R&D pipeline for most neglected diseases remains weak, and unlikely to support registration of novel drug classes that meet desired target product profiles in the short term. This calls for sustained investment as well as greater emphasis in the risky upstream drug discovery. Ac...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Solomon Nwaka, Bernadette Ramirez, Reto Brun, Louis Maes, Frank Douglas, Robert Ridley
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2009
Materias:	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/aa297590665b44bd8a8e90afb87e0b31
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aa297590665b44bd8a8e90afb87e0b31
record_format	dspace
spelling	oai:doaj.org-article:aa297590665b44bd8a8e90afb87e0b312021-11-25T06:33:13ZAdvancing drug innovation for neglected diseases-criteria for lead progression.1935-27271935-273510.1371/journal.pntd.0000440https://doaj.org/article/aa297590665b44bd8a8e90afb87e0b312009-08-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19707561/?tool=EBIhttps://doaj.org/toc/1935-2727https://doaj.org/toc/1935-2735The current drug R&D pipeline for most neglected diseases remains weak, and unlikely to support registration of novel drug classes that meet desired target product profiles in the short term. This calls for sustained investment as well as greater emphasis in the risky upstream drug discovery. Access to technologies, resources, and strong management as well as clear compound progression criteria are factors in the successful implementation of any collaborative drug discovery effort. We discuss how some of these factors have impacted drug discovery for tropical diseases within the past four decades, and highlight new opportunities and challenges through the virtual North-South drug discovery network as well as the rationale for greater participation of institutions in developing countries in product innovation. A set of criteria designed to facilitate compound progression from screening hits to drug candidate selection is presented to guide ongoing efforts.Solomon NwakaBernadette RamirezReto BrunLouis MaesFrank DouglasRobert RidleyPublic Library of Science (PLoS)articleArctic medicine. Tropical medicineRC955-962Public aspects of medicineRA1-1270ENPLoS Neglected Tropical Diseases, Vol 3, Iss 8, p e440 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270
spellingShingle	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Solomon Nwaka Bernadette Ramirez Reto Brun Louis Maes Frank Douglas Robert Ridley Advancing drug innovation for neglected diseases-criteria for lead progression.
description	The current drug R&D pipeline for most neglected diseases remains weak, and unlikely to support registration of novel drug classes that meet desired target product profiles in the short term. This calls for sustained investment as well as greater emphasis in the risky upstream drug discovery. Access to technologies, resources, and strong management as well as clear compound progression criteria are factors in the successful implementation of any collaborative drug discovery effort. We discuss how some of these factors have impacted drug discovery for tropical diseases within the past four decades, and highlight new opportunities and challenges through the virtual North-South drug discovery network as well as the rationale for greater participation of institutions in developing countries in product innovation. A set of criteria designed to facilitate compound progression from screening hits to drug candidate selection is presented to guide ongoing efforts.
format	article
author	Solomon Nwaka Bernadette Ramirez Reto Brun Louis Maes Frank Douglas Robert Ridley
author_facet	Solomon Nwaka Bernadette Ramirez Reto Brun Louis Maes Frank Douglas Robert Ridley
author_sort	Solomon Nwaka
title	Advancing drug innovation for neglected diseases-criteria for lead progression.
title_short	Advancing drug innovation for neglected diseases-criteria for lead progression.
title_full	Advancing drug innovation for neglected diseases-criteria for lead progression.
title_fullStr	Advancing drug innovation for neglected diseases-criteria for lead progression.
title_full_unstemmed	Advancing drug innovation for neglected diseases-criteria for lead progression.
title_sort	advancing drug innovation for neglected diseases-criteria for lead progression.
publisher	Public Library of Science (PLoS)
publishDate	2009
url	https://doaj.org/article/aa297590665b44bd8a8e90afb87e0b31
work_keys_str_mv	AT solomonnwaka advancingdruginnovationforneglecteddiseasescriteriaforleadprogression AT bernadetteramirez advancingdruginnovationforneglecteddiseasescriteriaforleadprogression AT retobrun advancingdruginnovationforneglecteddiseasescriteriaforleadprogression AT louismaes advancingdruginnovationforneglecteddiseasescriteriaforleadprogression AT frankdouglas advancingdruginnovationforneglecteddiseasescriteriaforleadprogression AT robertridley advancingdruginnovationforneglecteddiseasescriteriaforleadprogression
_version_	1718413700339073024

Advancing drug innovation for neglected diseases-criteria for lead progression.

Ejemplares similares